iBio (NYSEMKT:IBIO) Stock Price Up 2.9% – Should You Buy?

iBio, Inc. (NYSEMKT:IBIO)’s stock price traded up 2.9% on Tuesday . The stock traded as high as $2.50 and last traded at $2.45. 699,463 shares changed hands during mid-day trading, an increase of 518% from the average session volume of 113,212 shares. The stock had previously closed at $2.38.

iBio Stock Performance

The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.04. The stock has a market cap of $85.32 million, a price-to-earnings ratio of -2.47 and a beta of 1.26. The company has a 50 day simple moving average of $2.18 and a 200 day simple moving average of $1.46.

About iBio

iBio, Inc is a clinical-stage biotechnology company that develops recombinant proteins and vaccine candidates using proprietary plant-based expression systems. Headquartered in Bryan, Texas, the company leverages its Fast Expression System Technology (FAST) and LAMP™ molecular farming platforms to accelerate the design and production of complex biologics. These platforms capitalize on Nicotiana benthamiana plants as biofactories, enabling rapid, scalable expression of target proteins without the need for mammalian cell cultures.

The company’s pipeline includes vaccine candidates against viral pathogens and therapeutic proteins for immuno-oncology and infectious diseases.